

Claims

- Sue P
- 5 1. A DNA whose nucleotide sequence comprising the sequence selected from about 145 to about 4152 in the sequence listing in Figure 1.
- 10 2. A DNA of claim 1, wherein said DNA comprises the sequence selected from about 193 to about 4152 in the sequence listing in Figure 1.
- 15 3. A DNA of claim 1, wherein said DNA comprises the sequence from about 145 to about 4152 in the sequence listing in Figure 1.
- 20 4. A DNA of claim 1, wherein said DNA comprises the sequence from about 193 to about 4152 in the sequence listing in Figure 1.
- 25 5. A vector comprising a DNA of claim 1.
- 30 6. A vector of claim 5, wherein said vector is a plasmid or virus.
- 35 7. A nucleic acid construct comprising at least one DNA of claim 1.
- 40 8. A nucleic acid construct of claim 7, further comprising an effector gene, wherein said DNA activates the transcription of said effector gene.
- 45 9. A nucleic acid construct of claim 8, wherein said DNA is upstream of the effector gene.
- 50 10. A nucleic acid construct of claim 9, wherein said effector gene is a stearoyl-CoA desaturase gene.
- 55 11. A nucleic acid construct of claim 10, wherein said effector gene is human stearoyl-CoA desaturase gene.

- Sukh
5
- 10
- 15
- 20
- 25
- 30
12. A host cell that comprises a nucleic acid construct of claim 7.
 13. A host cell that comprises a nucleic acid construct of claim 8.
 14. A method for determining whether an agent effects the expression level of the effector gene in a host cell of claim 13, which comprises the steps of (i) contacting the agent under suitable conditions with such host cell expressing such effector gene at a known level; and (ii) determining whether the effector gene expression level increases or decreases after cellular contact with said agent.
 15. A method of claim 14, wherein said effector gene is a stearoyl-CoA desaturase gene.
 16. A method of claim 14, wherein said effector gene is human stearoyl-CoA desaturase gene.
 17. A method of claim 14, wherein said effector gene is a luciferase gene.
 18. A method of claim 14, wherein said effector gene is a β -galactosidase gene or a cloramphenicol acetyltransferase gene.
 19. A composition comprising a nucleic acid that comprises the sequence from about 145 to about 4152 in the sequence listing in Figure 1 having promoter activity, or a partial sequence of the promoter which possesses promoter activity, in a carrier.
 20. A composition comprising a nucleic acid that comprises the sequence from about 193 to about 4152 in the sequence listing in Figure 1 having promoter activity, or a partial sequence of the promoter which possesses promoter activity, in a carrier.